Olaparib Plus Vistusertib Promising in Early Trial of Endometrial, Other Cancers

Dave LevitanJun 6, 2018The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.

Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news